According to Towards Healthcare research, the
global stem
cell banking market is valued at USD 7.85 billion in 2024 and is
expected to increase to USD 9.12 billion in 2025. Over the forecast period from
2025 to 2034, the market is projected to grow at a robust CAGR of 16.14%,
reaching approximately USD 35.12 billion by 2034.
The major growth factors that positively affect market
growth are the growing demand for personalized medicines, increasing awareness
about stem cell preservation, and technological innovations. Favorable
regulatory support and increasing investments by government and private
organizations contribute to market growth. The rising prevalence of chronic
disorders, such as cancer, neurological disorders, and genetic disorders,
potentiates the demand for stem cell therapy.
The Complete Study is Now Available for
Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5867
The Stem Cell Banking Market: Highlights
➢ North America dominated the global market in 2024.
➢ Asia-Pacific is expected to grow at the fastest CAGR in the
market during the forecast period.
➢ By type of stem cell, the umbilical cord stem cell banking
segment held the largest revenue share of the market in 2024.
➢ By type of stem cell, the adipose tissue stem cell banking
segment is expected to grow with the highest CAGR in the market during the
studied years.
➢ By application, the therapeutic applications segment accounted
for the highest revenue share of the market in 2024.
➢ By end-use, the hospital & clinics segment led the market
in 2024.
➢ By end-use, the biotechnology & pharmaceutical companies
segment is expected to show the fastest growth in the coming years.
➢ By service type, the storage services segment held a major
revenue share of the market in 2024.
➢ By service type, the processing services segment is expected to
grow at the fastest CAGR in the market during the forecast period.
➢ By type of bank, the private stem cell banks segment registered
its dominance over the global market in 2024.
➢ By type of bank, the public stem cell banks segment is expected
to witness the fastest growth in the market over the forecast period.
What is Stem Cell Banking?
The stem cell banking market is experiencing robust growth,
driven by the increasing need for stem cells and advancements in cryogenic
technology. It refers to collecting and freezing a baby’s umbilical cord stem
cells. Stem cells can treat a wide range of life-threatening diseases, such as
bone marrow diseases, blood cancer, sickle cell disease, and immune system
disorders. Umbilical cord blood, cord tissue, and dental tooth pulp are rich
sources of stem cells. Healthcare professionals match the characteristics of
donated stem cells with the receiver.
You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com
Key Indicators and Highlights
Metric
Details
Market Size in 2025
USD 9.12 Billion
Projected Market Size in 2034
USD 35.12 Billion
CAGR (2025 – 2034)
16.14%
Leading Region
North America
Market Segmentation
By Type of Stem Cell, By Application, By End Use, By Service Type,
By Type of Bank, By Region
Top Key Players
Cord Blood Registry (CBR), Cryo-Cell International, ViaCord,
LifeCell International, StemCyte, Texas Cord Blood Bank, Neostem, Future
Health Biobank, AMAREX Clinical Research, Insception Lifeban, California
Cryobank, Umbilical Cord Blood Bank Ltd, Lonza Group AG, Regen Lab SA,
Macopharma, GenCure, Stempeutics Research, FamiCord Group, Cell Care India,
Medanta Stem Cell Facility
Automation: Major Potential
By introducing automation in stem cell banking, researchers
can improve efficiency and cell recovery rates, presenting future opportunities
for the stem cell banking market. These systems operate in a closed, sterile
environment to ensure the stability and viability of stem cells. Automated
systems lower cord blood processing costs and reduce the need for human
intervention. These advanced tools must be compliant with cGMP criteria and employ
an optical detection system to separate whole blood components. Additionally,
automation ensures consistent quality and performance of stem cell processing,
providing reliable and high-quality products.
High Cost: Major Limitation
The affordability of stem cell banking in a healthcare
facility, especially in developing and underdeveloped countries, is a major
limitation. The average cost of private cord blood banking ranges from $300 to
$2,300 for the collection, processing, and initial storage of stem cells.
Patients also need to pay an additional annual storage cost for stem cells. All
these impose a significant economic burden on the healthcare system.
The Stem Cell Banking Market: Regional Analysis
North America held a major revenue share of the market in
2024, due to the presence of a robust healthcare ecosystem, favorable
regulatory support, and increasing awareness. Government organizations actively
support the preservation and development of stem cell therapy. The increasing
number of stem cell banks in North American countries propels the market. There
are around 28 public umbilical cord blood banks in North America. The growing demand for personalized medicines
among patients necessitates that researchers and healthcare professionals
develop innovative therapeutics.
The United States (U.S.) government’s Health Resources &
Services Administration (HRSA) reported that over 246,500 cord blood units were
available on the C.W. Bill Young Cell Transplantation Program (CWBYCTP) donor
registry, as of September 2024. From October 2024 to May 2025, over 83,000 new
adult donor registrants were added to the registry, and 4,699 units were
provided to patients.
Canada is home to numerous public and private cord blood
banks, including Cells for Life, Canadian Blood Services Cord Blood Bank (CBS
CBB), and Future Health Biobank. Approximately 4,700 cord blood units have been
banked in CBS as of 2024. Since 80% of Canadians receive cord blood from
international donors, the Canadian government makes sufficient investment to
build an appropriate infrastructure.
Download the single region market report
@ https://www.towardshealthcare.com/checkout/5867
Asia-Pacific is expected to host the fastest-growing
market in the coming years.
The burgeoning healthcare sector and significant government
investment foster market growth. People are becoming aware of preserving
umbilical cord blood for future purposes. The increasing number of private and
public stem cell banks, as well as the rising adoption of advanced
technologies, propel the market. CordLife Group is Asia-Pacific’s largest
network of cord blood banks with full processing and cryopreservation storage
of stem cells. The increasing prevalence of chronic disorders facilitates the
use of stem cells as therapeutics.
Cord blood utilization is booming in China, with a total
inventory of donated cord blood units (CBU) of about 500,000, as of 2023. The
Chinese government is at the forefront of providing funding for the advancement
of stem cell banking infrastructure. SiChuan Cord Blood Bank, EuroStemCell, and
Global Cord Blood Corporation are some of the stem cell banks in China.
The Stem Cell Banking Market: Segmentation Analysis
By Type of Stem Cell
The umbilical cord stem cell banking segment held a dominant
presence in the market in 2024, due to the ability to replicate into any type
of human cell and the potential to treat a wide range of diseases. Umbilical
cord blood is easier to collect, store, and preserve for a long time. There is
a lower risk of rejection of the stem cell transplant when the source of the
hematopoietic stem cells is the umbilical cord. Additionally, umbilical cord
stem cells have lesser processing time than bone marrow stem cells and are
comparatively more affordable.
The adipose tissue stem cell banking segment is expected to
grow at the fastest CAGR in the market during the forecast period. Stem cells
derived from adipose tissues are essential for the repair and regeneration of
cartilage, bone, blood vessels, fibrous tissue, muscles, fat, and collagen.
Processing of about 300 ml of lipoaspirate can yield about 50 to 300 million mesenchymal
stem cells. Adipose tissue stem cell banking is widely preferred as it is a
convenient, abundant, and readily available source of stem cells, and the
harvest procedure is less invasive.
By Application
The therapeutic applications segment contributed the biggest
revenue share of the stem cell banking market in 2024, due to the growing need
for personalized medicines and the rising prevalence of chronic, genetic, and
rare disorders. According to a recent review, there were 115 clinical trials involving
83 distinct pluripotent stem cells for the treatment of ocular, neurological,
cardiovascular, hematological, and immunological disorders as of December 2024.
Ongoing efforts are made to develop stem cells for diverse disorders, which are
difficult to treat with conventional drugs.
The regenerative medicine sub-segment is expected to expand
rapidly. Stem cells are utilized in regenerative medicine to provide targeted
treatment to patients. They cure a disease from its root cause by self-renewing
and differentiating into specialized cell types. As of 2024, the U.S. Food and
Drug Administration (FDA) has approved a total of 9 stem cell therapies.
Get the latest insights on life science
industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By End-Use
The hospital & clinics segment held the largest revenue
share of the stem cell banking market in 2024, due to the availability of
favorable infrastructure and the increasing number of hospital admissions.
Hospitals and clinics possess suitable facilities for the storage and
processing of stem cells. Patients prefer hospitals and clinics for the
treatment of chronic disorders due to reimbursement policies and the presence
of skilled professionals. Skilled professionals provide multidisciplinary
expertise and personalized care to patients.
The biotechnology & pharmaceutical companies segment is
expected to grow with the highest CAGR in the market during the studied years.
Biotech & pharmaceutical companies conduct advanced research activities to
develop novel stem cell therapeutics. The increasing competition among key
players encourages companies to expand their product pipeline and strengthen
their market position. The growing number of biotech startups further
potentiates the demand for stem cells.
By Service Type
The storage services segment accounted for the highest
revenue share of the stem cell banking market in 2024, due to the need for
long-term storage requirements of stem cells and the availability of suitable
storage facilities. Stem cell banks possess equipment and infrastructure to
maintain ultra-cold temperatures. Stem cells are maintained at around -196 °C using
liquid nitrogen. They are stored for future medical purposes. Several studies
have demonstrated that stem cells stored for 25-30 years retain potency, and
when kept at 196oC, they can remain viable for a longer period.
The processing services segment is expected to witness the
fastest growth in the market over the forecast period. After collecting stem
cells, they are processed and tested for cell viability and potential
contamination. Stem cell processing is the most crucial step, as contamination
may lead to deterioration of stem cells. Researchers develop proprietary
technologies for stem cell processing to ensure higher yields of viable cells
for effective therapeutic applications.
By Type of Bank
The private stem cell banks segment led the stem cell
banking market in 2024, due to tailored services and customized benefits.
Private banks store and provide access to stem cells for family members only.
They offer exclusive ownership and accessibility rights to families for a long
period. This benefits patients during medical emergencies as stem cells are
readily available for transplantation. In addition, private banks ask for a
one-time fee for storing cord blood stem cells.
The public stem cell banks segment is expected to show the
fastest growth in the coming years. The demand for public stem cell banks is
increasing due to their cost-effectiveness and the presence of a large
inventory. Public banks provide access to stem cells from any donor after HLA
matching, supporting allogeneic stem cell transplantation. Stem cells from
public banks can also be provided for research purposes.
Become a valued research partner with us
– https://www.towardshealthcare.com/schedule-meeting
Top Companies & Their Contributions to the Market
Companies
Contributions
& Offerings
Cryoviva
India
Cryoviva is
the only Indian multinational cord blood bank, providing high-quality
umbilical cord stem cell banking.
Cryo-Cell
The
Florida-based company is the world’s first private cord blood bank trusted by
over 500,000 parents from 87 countries.
Future Health
Biobank
It transports
stem cell samples for free across 75 countries worldwide, with the presence
of 2 stem cell labs in the UK & Switzerland.
Famicord
Group
It provides
third-party companies with comprehensive solutions in the field of stem cell
banking, offering reliable and secure processing, testing, and storage.
Stem Cell Banking Market Top Companies
• Cord Blood Registry (CBR)
• ViaCord
• LifeCell International
• StemCyte
• Texas Cord Blood Bank
• Neostem
• AMAREX Clinical Research
• Insception Lifeban
• California Cryobank
• Umbilical Cord Blood Bank Ltd
• Regen Lab SA
• Macopharma
• GenCure
Download the Competitive Landscape market
report @ https://www.towardshealthcare.com/checkout/5867
Browse More Insights of Towards
Healthcare:
The global placental
stem cell therapy for neurological disorders market was valued at US$
453.4 million in 2024, rising to US$ 535.63 million in 2025, and is projected
to reach approximately US$ 2,366.97 million by 2034. The market is anticipated
to expand at a CAGR of 18.14% from 2025 to 2034, driven by growing advancements
in regenerative medicine and the rising prevalence of neurological disorders.
The global autologous
stem cell and non-stem cell therapies market is estimated at US$ 5.15
billion in 2024, increasing to US$ 6.81 billion in 2025, and forecasted to
achieve around US$ 82.32 billion by 2034. This represents a strong CAGR of
32.26% over the period, supported by the rapid adoption of personalized
treatment approaches and the expanding scope of regenerative therapies.
The global stem
cell assay market reached US$ 2.68 billion in 2024, growing to US$ 3.15
billion in 2025, and is expected to attain approximately US$ 13.5 billion by
2034. The market is advancing at a CAGR of 17.55% between 2025 and 2034, fueled
by the increasing use of stem cell assays in drug discovery, toxicity testing,
and quality control applications.
The global stem
cell reconstructive market was valued at US$ 1.56 billion in 2024, rose
to US$ 1.88 billion in 2025, and is projected to reach nearly US$ 10.32 billion
by 2034, expanding at a CAGR of 20.81%. Growth is attributed to advancements in
reconstructive therapies and the growing clinical acceptance of stem cell-based
interventions for tissue repair and regeneration.
The global stem
cell manufacturing market was valued at US$ 14.22 billion in 2024,
growing to US$ 15.83 billion in 2025, and is anticipated to reach around US$
41.67 billion by 2034. The market is projected to expand at a CAGR of 11.35%
during the forecast period, driven by increased investment in cell therapy
manufacturing facilities and advancements in automation and bioprocessing
technologies.
The global cancer
stem cells market was valued at US$ 3.2 billion in 2024, increased to
US$ 3.51 billion in 2025, and is forecasted to reach approximately US$ 8.04
billion by 2034, reflecting a CAGR of 9.64%. The market is being driven by the
rising incidence of cancer and ongoing R&D targeting tumor-initiating cells
for more effective oncology treatments.
The global induced
pluripotent stem cells (iPSCs) production market was valued at US$ 1.66
billion in 2024, grew to US$ 1.82 billion in 2025, and is projected to reach
nearly US$ 4.11 billion by 2034, expanding at a CAGR of 9.47%. The growth is
propelled by increasing demand for iPSCs in regenerative medicine, disease modeling,
and drug screening applications.
The global induced
pluripotent stem cells (iPSCs) market stood at US$ 1.93 billion in
2024, advanced to US$ 2.13 billion in 2025, and is estimated to achieve
approximately US$ 5.12 billion by 2034, growing at a CAGR of 10.25%. The
expansion of this market is supported by growing research funding and
technological innovations enhancing stem cell reprogramming efficiency.
Recent Developments in the Stem Cell Banking Market
➢ In March 2025, Abu Dhabi Biobank launched new private cord
blood banking services to increase accessibility of stem cells globally. The
bank will preserve samples locally, safely, and securely for up to 30 years at
its facility in Masdar City. The services will offer flexible payment plans,
advanced biobanking technology, and additional benefits like newborn screening.
➢ In November 2024, Sidra Medicine launched the country’s first
state-of-the-art cord blood banking service to enable families to preserve
their newborns’ stem cells in Qatar. The service is provided in collaboration
with CellSave Arabia, a leader in stem cell banking services.
➢ In September 2024, Cordlife Group announced that it received
approval to resume its cord blood banking activities in Singapore in a
controlled manner. The company also launched its enhanced processing and
storage facility to strengthen operational protocols and an advanced laboratory
monitoring system.
The Stem Cell Banking Market Segmentation
By Type of Stem Cell
• Umbilical Cord Stem Cell Banking
○ Cord Blood
Stem Cells
○ Cord Tissue
Stem Cells
• Bone Marrow Stem Cell Banking
• Peripheral Blood Stem Cell Banking
• Adipose Tissue Stem Cell Banking
• Other Stem Cell Banking
○ Amniotic
Fluid Stem Cells
○ Dental Pulp
Stem Cells
○ Induced
Pluripotent Stem Cells (iPSC)
By Application
• Therapeutic Applications
○ Oncology
(Blood Cancers, Solid Tumors)
○ Hematological
Disorders (Anemia, Thalassemia)
○ Immune
Disorders
○ Regenerative
Medicine (Orthopedics, Neurology, Cardiovascular)
○ Others
(Wound Healing, Autoimmune Diseases)
• Research & Development
• Cosmetic Applications
By End-Use
• Hospitals & Clinics
• Research & Academic Institutes
• Biotechnology & Pharmaceutical
Companies
• Private Consumers (Private Stem Cell
Banks)
• Others
By Service Type
• Collection Services
• Processing Services
• Storage Services
• Distribution Services
By Type of Bank
• Private Stem Cell Banks
• Public Stem Cell Banks
• Community Stem Cell Banks
By Region
• North America
○ U.S.
○ Canada
• Asia Pacific
○ China
○ Japan
○ India
○ South Korea
○ Thailand
• Europe
○ Germany
○ UK
○ France
○ Italy
○ Spain
○ Sweden
○ Denmark
○ Norway
• Latin America
○ Brazil
○ Mexico
○ Argentina
• Middle East and
Africa (MEA)
○ South Africa
○ UAE
○ Saudi Arabia
○ Kuwait
Immediate Delivery Available | Buy This
Premium Research @ https://www.towardshealthcare.com/checkout/5867
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical
research services, and advanced analytics, with a strong
emphasis on life science research. Dedicated to
advancing innovation in the life sciences sector, we build strategic
partnerships that generate actionable insights and transformative
breakthroughs. As a global strategy consulting firm, we empower life science
leaders to gain a competitive edge, drive research excellence, and accelerate
sustainable growth.
You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region:
+91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest